Answers are grounded in this paper and cite their sources.
Thus far, no clinically validated circulating biomarkers for managing both primary and secondary CNS lymphomas exist. There is need of standardization of biofluid collection, choice of analytes, and type of technique to perform the molecular analysis. The various assays should be evaluated through well-organized central testing within clinical trials.
No takes yet. Share an insight, caveat, or question.
Nayak et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: